thromboserin

Thromboserin (O-acetylsalicyloyl-L-serine) is an experimental antiplatelet agent developed by researchers at Imperial College London. It is a serine-linked prodrug of aspirin (acetylsalicylic acid) designed to inhibit platelet aggregation while potentially offering an improved safety profile, specifically by reducing the risk of gastrointestinal toxicity and bleeding complications compared to conventional aspirin. The drug was the focus of the planned Phase II NO BLE (NO BLEeding excess) trial, which intended to evaluate its clinical outcomes and bleeding risk in patients undergoing coronary artery bypass grafting (CABG). However, the study was never initiated because the clinical objectives were no longer considered viable in the context of contemporary medical practice. Thromboserin functions by releasing aspirin, which then irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2), thereby preventing the synthesis of thromboxane A2.

Other names

O-acetylsalicyloyl-L-serineaspirin-serine